Oncogene News and Research

RSS

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.

VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor

Co-founded back in 2014 by VHIO's Laura Soucek, CEO of the enterprise, and Marie-Eve Beaulieu, Chief Scientific Officer (CSO) of the company, VHIO-born spin-off Peptomyc S.L. has just announced that it has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc (OMO-103).

19 Mar 2021

New study sheds light on cancer metastasis

Breast cancer is harmful enough on its own, but when cancer cells start to metastasize -- or spread into the body from their original location -- the disease becomes even more fatal and difficult to treat.

12 Mar 2021

Study: Lowering the activity of KRAS gene can help fight pancreatic cancer

If clinicians could stop mutations of the KRAS gene in pancreatic cancer – which happens in more than 90 percent of pancreatic cancer cases and drastically reduces response to immunotherapy – the chances of improving treatment for this deadly form of cancer would be increased.

11 Mar 2021

Proteomics analysis from aggressive human cancers can help identify potential therapeutic targets

Researchers at Baylor College of Medicine show that analysis of the proteomics, or all the protein data, from aggressive human cancers is a useful approach to identify potential novel therapeutic targets.

4 Mar 2021

Researchers develop mutant gene-targeted immunotherapy approach to fight cancers

A novel targeted immunotherapy approach developed by researchers at the Ludwig Center, the Lustgarten Laboratory, and Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center employs new antibodies against genetically altered proteins to target cancers.

1 Mar 2021

Efficacy of polymeric nano-micelles depends on expression level of c-Myc

The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery (Prof. Tatsuya Yamasoba) and the group of Prof. Horacio Cabral of the Department of Bioengineering (Prof. Ryo Miyake) in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogene, has been developed.

27 Feb 2021

Specific cell-to-cell communication associated with progression of gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are a subytpe of cancers known as sarcomas. GIST is the most common type of sarcoma with approximately 5,000 to 6,000 new patient cases annually in the United States.

18 Feb 2021

Lund researchers discover how E. coli bacteria target and degrade MYC oncogene

Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer.

13 Feb 2021

Disrupting cancer cell cycle with two commercially available inhibitors causes tumor cell death

With two commercially available inhibitors, the cell cycle of the cancer cells in the childhood tumor neuroblastoma can be disrupted at a key point causing tumor cell death.

12 Feb 2021

ZyCoV-D DNA vaccine immunogenic against SARS-CoV-2 in animal models

In the absence of effective therapeutics or preventives, vaccines have become the focus of attention. Though over 170 vaccines are in preclinical and about 60 in clinical development, very few are based on plasmid DNA technology. However, a new preprint research paper posted to the bioRxiv* server reports the immunogenicity of a DNA vaccine candidate.

2 Feb 2021

RPS-12 protein overproduction appears to trigger breast cancer and other malignancies

Using the developing eye of the fruit fly as a test platform, researchers found that RPS-12 protein overproduction appears to trigger triple-negative breast cancer and possibly some other malignancies.

29 Jan 2021

Master Regulator proteins control cancer transcriptional identity

Thousands of different genetic mutations have been implicated in cancer, but a new analysis of almost 10,000 patients found that regardless of the cancer's origin, tumors could be stratified in only 112 subtypes and that, within each subtype, the Master Regulator proteins that control the cancer's transcriptional state were virtually identical, independent of the specific genetic mutations of each patient.

11 Jan 2021

Biologist receives NIH grant to build software tools to predict cancer drug efficacy

One of the most promising areas of human cancer research is the study of signal transduction, or cell signaling.

4 Jan 2021

Hematoxylin compounds can selectively kill CALR mutant cancer cells

Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR).

10 Dec 2020

Long-range regulation of tumor suppressor genes plays key role in cancer

Enhancers are regulatory elements that play an important role in cancer.Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, identified a novel enhancer.

25 Nov 2020

UVA researchers discover gene responsible for the metastasis of triple-negative breast cancer

University of Virginia Cancer Center researchers have identified a gene responsible for the spread of triple-negative breast cancer to other parts of the body - a process called metastasis - and developed a potential way to stop it.

20 Nov 2020

Two studies find age as a primary factor in melanoma treatment resistance

Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response.

2 Nov 2020

Genetic alterations linked to high incidence of prostate cancer in African American men

Prostate cancer tumors from African American men had higher frequencies of certain genetic alterations that may be associated with aggressive disease, compared with prostate cancer tumors from white men.

28 Oct 2020

Researchers find a new therapeutic approach to combat leukemia

Leukemia frequently originates from the so-called leukemic stem cell, which resides in a tumor promoting and protecting niche within the bone marrow. Scientists from the Max Planck Institute of Biochemistry in Martinsried, Germany, have found a new way to make these cells vulnerable by specifically dislodging these cells from their niches.

23 Oct 2020

Androgen deprivation strategies could help mitigate SARS-CoV-2 infection

Since the beginning of the COVID-19 pandemic, researchers have noted that women are generally less severely affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This has led to the exploration into estrogen and androgens' role in the hyperinflammatory clinical phenotypes of COVID-19. A recent study published on the preprint server bioRxiv shows that drugs targeting androgens and TMPRSS2 inhibitors may potentially combat the pandemic.

20 Oct 2020